Delivering a '1-2 punch' to RAS-driven cancers
The status, timeline and source of this project. A free account opens every field.
Source: EU Funding & Tenders Portal
Resistance to current anticancer therapies remains a major public health burden, driving a substantial number of cancer-related deaths in the EU and worldwide. In particular, KRAS-driven lung cancer – one of the most aggressive tumour types – urgently requires new strategies, as resistance to the approved KRAS-G12C inhibitors almost invariably emerges within months after treatment, undermining the
- Status
- Prospective
- Sector
- Commercial
- Location
- Sweden
- Updated
- 19 Nov 2026
- Source
- EU Funding & Tenders Portal
ConstructChat
Ask ConstructChat about Delivering a '1-2 punch' to RAS-driven cancers
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
| Not available for this record. |
Status
Original status | forthcoming |
Taiyo status | Prospective |
Taiyo last update | 2026-11-19 |
Contact
| Not available for this record. |
Description
Description | Resistance to current anticancer therapies remains a major public health burden, driving a substantial number of cancer-related deaths in the EU and worldwide. In particular, KRAS-driven lung cancer – one of the most aggressive tumour types – urgently requires new strategies, as resistance to the approved KRAS-G12C inhibitors almost invariably emerges within months after treatment, undermining their clinical benefit. Mounting evidence highlights that cancer cells can adopt a dynamic and heterogeneous tolerant state early upon treatment, allowing the survival of a small fraction of cancer cells that later fuels resistance and, ultimately, patient relapse. Yet, targeting this tolerant phase remains insufficiently explored to translate to clinical practice that proactively targets cancer resistance. Therefore, RAS-PUNCH aims to overcome this challenge by pioneering a sequential ‘1-2 punch’ strategy that first reprograms and then eliminates tolerant cells in KRAS-driven lung cancer, building on their unique dynamic and heterogeneous nature. Moving beyond conventional strategies, RAS-PUNCH will comprehensively define the phenotypic plasticity underlying RAS inhibitor-induced tolerance, identify small molecule ‘reprogrammers’ through high-throughput phenotypic screening and integrate them into a preclinical ‘1-2 punch’ framework. By delivering the first phenotypic atlas of RAS inhibitor-induced heterogeneity and advancing mechanistically informed ‘1-2 punch’ strategies, RAS-PUNCH addresses a central unmet need in oncology. The expected outcomes will provide proof-of-concept for innovative sequential treatments that prevent resistance in lung cancer, with potential to extend across multiple cancer types. In doing so, the project directly contributes to the EU Cancer Mission’s ambition of saving and improving the lives of cancer patients. |
Location
Country | Sweden |
Source
Source | EU Funding & Tenders Portal |
URL |
More Details
Record type | Project |
Sector | Commercial |
Article published date | 2026-11-15 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
